Cost-effectiveness model: Glycoprotein Antagonists
This is the cost-effectiveness model comparing alternative management strategies for the use of Glycoprotein IIb/IIIa antagonists in non-ST-elevation acute coronary syndrome.
Cost-effectiveness model: Glycoprotein Antagonists
15 May 2002 (956.57 Kb 38 sec) |
This page was last updated: 30 March 2010